Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of bevacizumab + S-1 + raltitrexed in refractory metastatic colorectal cancer
ChiCTR1900020485Phase 2Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Sep 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab, tegafur and raltitrexed in metastatic colorectal adenocarcinoma (mCRC), sponsored by West China Hospital of Sichuan University. Primary endpoint: Objective response rate. Started Sep 2015; status: recruiting.
02
Drugs
bevacizumabtegafurraltitrexed
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on ChiCTR1900020485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900020485.